Oragenics Inc (NYSEAMERICAN: OGEN) is running for the top early on in the trading session this morning, enjoying high volume.
The gains are ultimately the result of news that the company has received approval to enroll patients from Germany and Europe into a Phase 2 clinical trial.
The clinical trial is assessing AG013 as a potential option for the prvention and treatment of OM.
To date, the treatment has been granted Fast Track Designation in the United States and Orphan Drug Status in Europe.
During the trial, the company will assess the safety, tolerability and efficacy of AG013 in approximately 200 patients.
As a result of the enrollment news, OGEN is headed up. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:46), OGEN is trading at $0.95 per share after a gain of $0.06 per share or 6.71% thus far today.
View our full report on the OGEN story here!
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!